Results 151 to 160 of about 118,446 (304)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

BMEMat, EarlyView.
Sequential dual‐catalytic treatment of the gout wound ulceration process by CDs‐Uri@PDA. (a) Synthesis steps and morphology of CDs‐Uri@PDA. (b) Sequential treatment process and mechanism of CDs‐Uri@PDA for gout wound ulceration according to (i) uric acid reduction, (ii) antibacterial activity, and (iii) anti‐inflammatory effects.
Yonglan Yang, Yang Yang, Pengpeng Ma, Ruiqi Zhu, Xia Pan, Shaoling Zheng, Bo Chen, Yanli Jin, Youcong Gong, Jie Liu, Tianwang Li, Xu Chen   +11 more
wiley   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

The Epidemiological Landscape and Burden of Chronic Disease in Australia: Contextualizing the Distinct Profile of Tasmania

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Chronic diseases are the leading causes of morbidity and mortality worldwide and impose a substantial and long‐lasting burden on individuals, families, communities, and healthcare systems. In Australia, more than 47% of the population had at least one chronic condition in 2018, and the prevalence rose sharply with age: approximately 80% of ...
Getahun Kebede Beyera
wiley   +1 more source

Addressing Rheumatic Heart Disease in the Pacific

Background/Purpose: Pacific leaders have articulated addressing rheumatic heart disease (RHD) as a Pacific health priority [...
Joseph H. Kado, Christine Everest, Jessica N. Daw, Rosemary Wyber   +3 more
core   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

Sex Differences in Social, Health, and Lifestyle Characteristics Associated With Binge‐Eating Behaviors: Results From a French National Random Population‐Based Study

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective To explore sex differences in social, health and lifestyle characteristics associated with binge‐eating behaviors in a large population‐based study. Method This study included 84,995 participants (women 52.1%) aged ≥ 15 years from the French national random population‐based EpiCov cohort.
Junko Kose, Nathalie Godart, Anne Pastorello, Caroline Huas, Alexandra Rouquette, EpiCov Study Group, Josiane Warszawski, Nathalie Bajos, Guillaume Bagein, François Beck, Emilie Counil, Florence Jusot, Nathalie Lydié, Claude Martin, Laurence Meyer, Philippe Raynaud, Alexandra Rouquette, Ariane Pailhé, Delphine Rahib, Patrick Sillard, Rémy Slama, Alexis Spire   +21 more
wiley   +1 more source

The global burden of rheumatic heart disease: 1990-2021. [PDF]

Clin Med (Lond)
Safiri S, Aletaha R, Amiri F, Sullman MJM, Rahmanian M, Singh K, Kolahi AA.   +6 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. [PDF]

JACC Asia
Morel O, Mai AT, Zühlke L, Jouven X, Marchandot B, Pressman G, Patton-Bolman C, Roffi M, Pibarot P.   +8 more
europepmc   +1 more source